Although the majority of Alzheimer's disease (AD) cases are sporadic, about 5% of cases are inherited in an autosomal dominant pattern as familial AD (FAD) and manifest at an early age. Mutations in the presenilin 1 (PSEN1) gene account for the majority of early-onset FAD. Here, we describe the generation of virus-free human induced pluripotent stem cells (hiPSCs) derived from fibroblasts of patients harboring the FAD PSEN1 mutation A246E and fibroblasts from healthy age-matched controls using nonintegrating episomal vectors. We have differentiated these hiPSC lines to the neuronal lineage and demonstrated that hiPSC-derived neurons have mature phenotypic and physiological properties. Neurons from mutant hiPSC lines express PSEN1-A246E mutations themselves and show AD-like biochemical features, that is, amyloidogenic processing of amyloid precursor protein (APP) indicated by an increase in β-amyloid (Aβ)42/Aβ40 ratio. FAD hiPSCs harboring disease properties can be used as humanized models to test novel diagnostic methods and therapies and explore novel hypotheses for AD pathogenesis.
Get full access to this article
View all access options for this article.
References
1.
AlzheimerA. (1911). Ueber eigenartige Krankheitsfaelle des spaeteren Alters. Z Ges Neurol Psychiat, 4:356–385.
2.
WalshDM and SelkoeDJ. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 44:181–193.
3.
YanknerBA, DawesLR, FisherS, Villa-KomaroffL, Oster-GraniteML and NeveRL. (1989). Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science, 245:417–420.
4.
YanknerBA. (1996). Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron, 16:921–932.
5.
SisodiaSS and St George-HyslopPH. (2002). gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?. Nat Rev Neurosci, 3:281–290.
6.
SmallSA and DuffK. (2008). Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron, 60:534–542.
7.
SherringtonR, RogaevEI, LiangY, RogaevaEA, LevesqueG, IkedaM, ChiH, LinC, LiG, et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 375:754–760.
8.
CrutsM, van DuijnCM, BackhovensH, Van den BroeckM, WehnertA, SerneelsS, SherringtonR, HuttonM, HardyJ, et al. (1998). Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet, 7:43–51.
9.
SelkoeDJ. (2001). Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A, 98:11039–11041.
10.
MattisVB and SvendsenCN. (2001). Induced pluripotent stem cells: a new revolution for clinical neurology?. Lancet Neurol, 4:383–394.
11.
DimosJT, RodolfaKT, NiakanKK, WeisenthalLM, MitsumotoH, ChungW, CroftGF, SaphierG, LeibelR, et al. (2008). Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 321:1218–1221.
12.
ChiangCH, SuY, WenZ, YoritomoN, RossCA, MargolisRL, SongH and MingGL. (2011). Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol Psychiatry, 16:358–360.
ZhangN, AnMC, MontoroD and EllerbyLM. (2010). Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr, 2:RRN1193
IsraelMA, YuanSH, BardyC, ReynaSM, MuY, HerreraC, HefferanMP, Van GorpS, NazorKL, et al. (2012). Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature, 482:216–220.
17.
KondoT, AsaiM, TsukitaK, KutokuY, OhsawaY, SunadaY, ImamuraK, EgawaN, YahataN, et al. (2013). Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell, 12:487–496.
18.
YamanakaS. (2007). Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell, 1:39–49.
19.
KnoepflerPS. (2008). Why myc?. An unexpected ingredient in the stem cell cocktail. Cell Stem Cell, 2:18–21.
20.
WeiD, KanaiM, HuangS and XieK. (2006). Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis, 27:23–31.
21.
OkitaK, IchisakaT and YamanakaS. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448:313–317.
22.
YuJ, HuK, Smuga-OttoK, TianS, StewartR, SlukvinII and ThomsonJA. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324:797–801.
23.
OkitaK, NakagawaM, HyenjongH, IchisakaT and YamanakaS. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322:949–953.
24.
StadtfeldM, NagayaM, UtikalJ, WeirG and HochedlingerK. (2008). Induced pluripotent stem cells generated without viral integration. Science, 322:945–949.
25.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, WaknitzMA, SwiergielJJ, MarshallVS and JonesJM. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282:1145–1147.
26.
BurridgePW, ThompsonS, MillrodMA, WeinbergS, YuanX, PetersA, MahairakiV, KoliatsosVE, TungL and ZambidisET. (2011). A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One, 6:e18293
27.
PetersA and Zambidis.E (2011). Generation of nonviral integration-free induced pluripotent stem cells from plucked human hair follicles. In: Human Embryonic and Induced Pluripotent Stem Cells: Lineage-Specific Differentiation Protocols. KaimingY, ShaJ, eds. Springer Protocols Handbooks, Humana Press, New York, pp. 203–227.
28.
ParkTS, HuoJS, PetersA, TalbotCCJr., VermaK, ZimmerlinL, KaplanIM and ZambidisET. (2012). Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors. PLoS One, 7:e42838
29.
ParkIH, ZhaoR, WestJA, YabuuchiA, HuoH, InceTA, LerouPH, LenschMW and DaleyGQ. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451:141–146.
30.
ZhangSC, WernigM, DuncanID, BrüstleO and ThomsonJA. (2001). In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol, 19:1129–1133.
31.
NgES, DavisRP, AzzolaL, StanleyEG and ElefantyAG. (2005). Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood, 106:1601–1603.
32.
BurridgePW, AndersonD, PriddleH, Barbadillo MuñozMD, ChamberlainS, AllegrucciC, YoungLE and DenningC. (2007). Improved human embryonic stem cell embryoid body omogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells, 25:929–938.
33.
XuC, InokumaMS, DenhamJ, GoldsK, KunduP, GoldJD and CarpenterMK. (2001). Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol, 19:971–974.
34.
ChambersSM, FasanoCA, PapapetrouEP, TomishimaM, SadelainM and StuderL. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol, 27:275–280.
35.
MorizaneA, DoiD, KikuchiT, NishimuraK and TakahashiJ. (2011). Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. J Neurosci Res, 89:117–126.
36.
Ben-HurT, IdelsonM, KhanerH, PeraM, ReinhartzE, ItzikA and ReubinoffBE. (2004). Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells, 22:1246–1255.
37.
PeraMF, AndradeJ, HoussamiS, ReubinoffB, TrounsonA, StanleyEG, Ward-van OostwaardD and MummeryC. (2004). Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. J Cell Sci, 117:1269–1280.
38.
ChibaS, LeeYM, ZhouW and FreedCR. (2008). Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats. Stem Cells, 26:2810–2820.
39.
ElkabetzY, PanagiotakosG, Al ShamyG, SocciND, TabarV and StuderL. (2008). Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev, 22:152–165.
40.
NasonkinI, MahairakiV, XuL, HatfieldG, CummingsBJ, EberhartC, RyugoDK, MaricD, BarE and KoliatsosVE. (2009). Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells, 27:2414–2426.
41.
EirakuM, WatanabeK, Matsuo-TakasakiM, KawadaM, YonemuraS, MatsumuraM, WatayaT, NishiyamaA, MugurumaK and SasaiY. (2008). Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell, 3:519–532.
42.
SmithJR, VallierL, LupoG, AlexanderM, HarrisWA and PedersenRA. (2008). Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Dev Biol, 313:107–117.
43.
LiXJ, ZhangX, JohnsonMA, WangZB, LavauteT and ZhangSC. (2009). Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development, 136:4055–4063.
44.
SaitoT, HanaiS, TakashimaS, NakagawaE, OkazakiS, InoueT, MiyataR, HoshinoK, AkashiT, et al. (2011). Neocortical layer formation of human developing brains and lissencephalies: consideration of layer-specific marker expression. Cereb Cortex, 21:588–596.
45.
ScheunerD, EckmanC, JensenM, SongX, CitronM, SuzukiN, BirdTD, HardyJ, HuttonM, et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med, 2:864–870.
46.
LemereCA, LoperaF, KosikKS, LendonCL, OssaJ, SaidoTC, YamaguchiH, RuizA, MartinezA, et al. (1996). The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med, 2:1146–1150.
47.
HardyJ and SelkoeDJ. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297:353–356.
48.
WongPC, CaiH, BorcheltDR and PriceDL. (2002). Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci, 5:633–639.
49.
MuckeL, MasliahE, YuGQ, MalloryM, RockensteinEM, TatsunoG, HuK, KholodenkoD, Johnson-WoodK, and McConlogueL. (2000). High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci, 20:4050–4058.
50.
IsraelMA and GoldsteinLS. (2011). Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges. Genome Med, 3:49
51.
WolfeMS. (2007). When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep, 8:136–140.
52.
BentahirM, NyabiO, VerhammeJ, ToliaA, HorréK, WiltfangJ, EsselmannH, and De StrooperB. (2006). Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem, 96:732–742.
53.
BergmansBA and De StrooperB. (2010). gamma-Secretases: from cell biology to therapeutic strategies. Lancet Neurol, 9:215–226.
54.
HuBY, WeickJP, YuJ, MaLX, ZhangXQ, ThomsonJA and ZhangSC. (2010). Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A, 107:4335–4340.
55.
BoultingGL, KiskinisE, CroftGF, AmorosoMW, OakleyDH, WaingerBJ, WilliamsDJ, KahlerDJ, YamakiM, et al. (2011) A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol, 29:279–286.
56.
JacobsD, SanoM, MarderK, BellK, BylsmaF, LaflecheG, AlbertM, BrandtJ, and SternY. (1994). Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology, 44:1215–1220.
57.
RileyKP, SnowdonDA, DesrosiersMF and MarkesberyWR. (2005). Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging, 26:341–347.
58.
IaconoD, MarkesberyWR, GrossM, PletnikovaO, RudowG, ZandiP and TroncosoJC. (2009). The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology, 73:665–673.
59.
PriceDL, SisodiaSS and BorcheltDR. (1988). Genetic neurodegenerative diseases: the human illness and transgenic models. Science, 282:1079–1083.
60.
DodartJC, MathisC, BalesKR and PaulSM. (2002). Does my mouse have Alzheimer's disease?. Genes Brain Behav, 1:142–155.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
